See more : The Beauty Health Company (SKIN) Income Statement Analysis – Financial Results
Complete financial analysis of DBV Technologies S.A. (DBVT) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of DBV Technologies S.A., a leading company in the Biotechnology industry within the Healthcare sector.
- Rincon Resources Limited (RCR.AX) Income Statement Analysis – Financial Results
- PT Bali Towerindo Sentra Tbk (BALI.JK) Income Statement Analysis – Financial Results
- PSI Software AG (PSSWF) Income Statement Analysis – Financial Results
- Media Matrix Worldwide Limited (MMWL.BO) Income Statement Analysis – Financial Results
- Richly Field China Development Limited (0313.HK) Income Statement Analysis – Financial Results
DBV Technologies S.A. (DBVT)
About DBV Technologies S.A.
DBV Technologies S.A., a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its lead product candidate is Viaskin Peanut, an immunotherapy product, which has completed Phase III clinical trial for the treatment of peanut allergies in 4 to 11 years of age children, adolescents, and adults. The milk-induced company is also developing Viaskin Milk that is in Phase I/II clinical trial for the treatment of Immunoglobulin E (IgE) mediated cow's milk protein allergy (CMPA); Viaskin Egg, a pre-clinical stage product for the treatment of hen's egg allergy; and booster vaccine for Bordetella pertussis. Its other earlier stage research programs include a vaccine for the respiratory syncytial virus, as well as treatments for Crohn's disease, celiac disease, and type I diabetes. The company has a collaboration with Nestlé Health Science to develop MAG1C, a ready-to-use atopy patch test for the diagnosis of non-IgE mediated CMPA in infants and toddlers. DBV Technologies S.A. was incorporated in 2002 and is headquartered in Montrouge, France.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 15.73M | 4.80M | 5.71M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 240.98K | 332.67K | 333.43K | 297.52K | 213.05K |
| Cost of Revenue | 0.00 | 20.30M | 9.27M | 18.82M | 3.09M | 5.03M | 3.43M | 1.42M | 152.70K | 215.14K | 187.74K | 141.55K | 109.96K |
| Gross Profit | 15.73M | -15.50M | -3.57M | -18.82M | -3.09M | -5.03M | -3.43M | -1.42M | 88.28K | 117.54K | 145.69K | 155.96K | 103.09K |
| Gross Profit Ratio | 100.00% | -322.90% | -62.46% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 36.63% | 35.33% | 43.69% | 52.42% | 48.39% |
| Research & Development | 60.22M | 75.50M | 70.34M | 124.61M | 129.00M | 146.49M | 148.13M | 86.96M | 40.84M | 33.37M | 31.85M | 19.76M | 11.28M |
| General & Administrative | 25.16M | 24.30M | 30.52M | 41.87M | 55.77M | 54.23M | 49.85M | 38.42M | 20.03M | 12.81M | 11.57M | 7.88M | 4.05M |
| Selling & Marketing | -2.28M | 1.60M | 4.39M | 12.12M | 24.07M | 43.97M | 22.27M | 12.45M | 585.76K | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 22.88M | 25.90M | 34.91M | 53.98M | 79.85M | 98.20M | 72.13M | 50.86M | 20.61M | 12.81M | 11.57M | 7.88M | 4.05M |
| Other Expenses | 0.00 | 0.00 | 0.00 | -12.67M | -16.04M | -17.52M | -16.17M | -9.82M | -7.03M | -7.18M | -6.68M | -4.44M | -2.95M |
| Operating Expenses | 92.16M | 101.40M | 105.24M | 165.92M | 192.80M | 227.17M | 204.08M | 128.00M | 54.43M | 39.00M | 36.74M | 23.20M | 12.38M |
| Cost & Expenses | 92.16M | 101.40M | 105.24M | 165.92M | 192.80M | 227.17M | 204.08M | 128.00M | 54.58M | 39.22M | 36.93M | 23.34M | 12.49M |
| Interest Income | 3.78M | 406.29K | 440.79K | 0.00 | 85.15K | 673.86K | 867.09K | 1.67M | 1.21M | 1.15M | 1.23M | 883.09K | 105.44K |
| Interest Expense | 0.00 | 427.00K | 583.77K | 887.89K | 1.79M | 479.76K | 4.68M | 17.65K | 174.18K | 162.96K | 44.59K | 43.01K | 72.00K |
| Depreciation & Amortization | -4.57M | 20.30M | 9.27M | 18.82M | 3.09M | 5.03M | 3.43M | 1.42M | 1.28M | 813.52K | 625.73K | 480.40K | 288.18K |
| EBITDA | -87.46M | -76.68M | -79.77M | -162.74M | -181.37M | -206.16M | -176.90M | -126.29M | -53.62M | -36.00M | -29.56M | -21.68M | -11.88M |
| EBITDA Ratio | -556.11% | -2,012.50% | -1,759.90% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -21,512.88% | -11,099.55% | -10,418.58% | -7,286.80% | -5,575.59% |
| Operating Income | -76.43M | -96.63M | -98.61M | -194.80M | -192.80M | -227.17M | -204.08M | -128.00M | -54.34M | -38.89M | -36.59M | -23.04M | -12.27M |
| Operating Income Ratio | -485.97% | -2,013.15% | -1,727.65% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -22,547.53% | -11,689.15% | -10,974.91% | -7,745.10% | -5,760.35% |
| Total Other Income/Expenses | 3.71M | 431.00K | 8.99M | -24.67M | 9.20M | 15.56M | 19.85M | 1.66M | 1.04M | 986.34K | 1.19M | 840.08K | 33.44K |
| Income Before Tax | -72.72M | -96.20M | -98.19M | -195.69M | -194.51M | -226.98M | -207.90M | -126.35M | -53.30M | -37.90M | -35.41M | -22.20M | -12.24M |
| Income Before Tax Ratio | -462.35% | -2,004.17% | -1,720.22% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -22,116.35% | -11,393.08% | -10,619.61% | -7,462.73% | -5,744.65% |
| Income Tax Expense | 7.00K | 100.00K | -381.00K | -12.26K | 692.67K | 20.50K | 1.41K | 1.67M | 1.21M | 1.15M | 1.23M | 883.08K | 105.44K |
| Net Income | -72.73M | -96.30M | -97.81M | -195.68M | -195.20M | -227.00M | -207.90M | -126.35M | -53.30M | -37.90M | -35.41M | -22.20M | -12.24M |
| Net Income Ratio | -462.40% | -2,006.25% | -1,713.54% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -22,115.85% | -11,393.08% | -10,619.61% | -7,462.73% | -5,744.65% |
| EPS | -2.84 | -4.96 | -7.12 | -14.48 | -21.12 | -31.40 | -33.60 | -20.68 | -9.92 | -9.44 | -10.40 | -7.24 | -3.65 |
| EPS Diluted | -2.84 | -4.96 | -7.12 | -14.48 | -21.12 | -31.40 | -33.60 | -20.68 | -9.92 | -9.44 | -10.40 | -7.24 | -3.65 |
| Weighted Avg Shares Out | 23.78M | 19.35M | 13.77M | 13.52M | 9.25M | 7.23M | 6.18M | 6.11M | 5.37M | 4.02M | 3.40M | 3.07M | 3.35M |
| Weighted Avg Shares Out (Dil) | 23.78M | 19.35M | 13.77M | 13.52M | 9.25M | 7.23M | 6.19M | 6.11M | 5.38M | 4.02M | 3.40M | 3.08M | 3.35M |
DBV Technologies to Present at Upcoming Investor Conferences
Is DBV Technologies (DBVT) Stock Outpacing Its Medical Peers This Year?
DBV Technologies: Good Data, Plenty Of Cash And Regulatory Uncertainty
2 Biotechs That Recently Soared -- Are They Buys?
DBV Technologies to Present at the JMP Securities Life Sciences Conference in New York
Why DBV Technologies Stock Popped Again Today
Has DBV Technologies (DBVT) Outpaced Other Medical Stocks This Year?
Why DBV Technologies Was a Big Winner on Wednesday
HC Wainwright Says Viaskin Benefit Affirmed In Toddlers...What's Next?
DBV Technologies Shares Jump On Positive Data From Peanut Allergy Trial In Toddlers
Source: https://incomestatements.info
Category: Stock Reports